Home › Aortic Valve Stenosis › NCT07205341

Detecting Changes in Arterial Blood Volume and Cardiac Efficiency

A Pilot Clinical Study to Assess Correlation Between Arterial Blood Volume Status and Cardiac Efficiency, and HemoCept Device Data in Trans-Aortic Valve Replacement (TAVR} Surgery

Who can join

Ages 18 to 80 · All sexes

Inclusion Criteria:

* Subjects or representatives must have voluntarily signed the informed consent form before any study related procedures.
* Subjects can be any gender but must be between (and including) the ages of 18 and 80.
* Subject ls being treated by the participating healthcare facility .

  ., Subject requires a trans-aortic valve replacement.
* Subject is able and willing to provide informed consent and HIPM authorization.
* Subject is able and willing to meet all study requirements.

Exclusion Criteria:

* Subject is pregnant, breast-feeding, or intends to become pregnant during the course of the study.
* Subject has a personal medical history that includes:

  * Long O-T syndrome
  * Cardiac channelopathies
  * Seizures

About the study

The objective of this Pilot Study is to demonstrate the efficacy of the Hemocept device in detecting changes in arterial blood volume and cardiac efficiency.

Sponsor: HemoCept Inc. · Participants: 20 · Started: Apr 29, 2025

Contact the study team

• Katharine Adkins · Phone: 303-442-2395

Official record on ClinicalTrials.gov — NCT07205341

Locations in the U.S.

Conditions

• Aortic Valve Stenosis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.